Parkinson's and Diabetes. The Inevitable Crisis.

Parkinson's disease is a neurodegenerative condition that will affect a large segment of Mexico's population. Deploying the most advanced available treatments to build a healthier society should be a public health priority. On a personal note, my grandmother suffered from Parkinson's, a cruel disease that erodes the daily lives of those we love. Current advances in GLP-1 receptor agonist medications are making a real difference in managing and treating these conditions. In various medical circles in London, I have heard physicians describe Parkinson's and Alzheimer's as sub-diseases of diabetes, meaning that blood glucose control and insulin function represent the greatest obstacle to protecting against them. Below I share my summary of one of the most recently published articles in the International Journal of Molecular Sciences. Mexican public policy should evaluate a strategic partnership with GLP-1 receptor agonist manufacturers to treat the population with cutting-edge technology and thus improve the quality of life of Mexican patients, their families, and society as a whole.

Parkinson's disease (PD) is the second most common progressive brain disorder. In this disease, the brain cells that produce dopamine, a substance that helps control movement, begin to die. The primary treatment for Parkinson's focuses on replacing this lost dopamine to relieve symptoms, though it does not cure the disease.

Scientists have recently made an intriguing discovery: when insulin, the hormone that regulates blood sugar, does not function properly in the body, this may be connected to Parkinson's. In people with insulin resistance (a condition in which the body does not respond well to insulin), dopamine in the brain may be more vulnerable to damage. Researchers have also found that glucose metabolism is disrupted in several brain regions of people with Parkinson's. It has further been observed that type 2 diabetes increases the risk of developing Parkinson's.

A significant development is that certain medications already used to treat type 2 diabetes, known as GLP-1 receptor agonists, are showing signs of potential utility for treating Parkinson's as well. In both animal studies and early human trials, these medications have demonstrated the ability to restore dopamine levels in the brain, prevent further loss of brain cells, and reduce both motor symptoms and other manifestations of the disease.

Studies conducted with human participants using these medications, including exendin-4, liraglutide, and lixisenatide, have shown improvements in motor capacity and cognitive function (including memory and thinking), as well as in patients' daily quality of life. This has led researchers to consider that these medications could modify the course of Parkinson's, not merely treat its symptoms.

These medications may also benefit the brain in additional ways, including by reducing neuroinflammation, mitigating oxidative stress (a form of cellular damage), maintaining mitochondrial health (the cell's energy-generating structures), and helping cells manage misfolded or damaged proteins. All of these mechanisms are linked to how Parkinson's begins and progresses.

We are now awaiting the results of several ongoing clinical trials that will determine whether these medications can achieve something both difficult and hopeful: halting or even reversing the progression of this devastating disease.

Source: https://doi.org/10.3390/ijms25073812

Frequently Asked Questions

What is the connection between Parkinson's disease and diabetes?

Research suggests that insulin resistance and impaired glucose metabolism may play a role in the development of Parkinson's. Some physicians describe both Parkinson's and Alzheimer's as sub-diseases of diabetes, given the central role that insulin function plays in brain health.

How might GLP-1 receptor agonists help Parkinson's patients?

GLP-1 receptor agonists were originally developed for type 2 diabetes. Early clinical trials using drugs such as liraglutide and lixisenatide have shown improvements in motor function and cognitive performance in Parkinson's patients, suggesting these drugs may modify disease progression rather than merely treat its symptoms.

What are the policy implications for Mexico?

Given the projected burden of Parkinson's on Mexico's population, a strategic partnership with GLP-1 receptor agonist manufacturers could give the population access to cutting-edge treatment, improving the quality of life for patients, their families, and society as a whole.